Three decades in motion.
Highland Park High School graduate
Dallas. Class of 1995. Foundation of the lifelong Dallas operating network and the Highland Park alumni community engagement that continues to this day.
Hillman Ventures founded
Established the private family office in Dallas with a thesis around patient capital deployed against FDA regulatory milestones. The structural choice that defined the next three decades of work.
Affinity Healthcare Systems Inc
Co-founder. Built ventures across FDA-regulated specialty medical services. Exited to
Dynacq Healthcare (NASDAQ: DYII).
PPM Rehabilitation
Co-founder. Rehabilitation services platform across the Dallas–Fort Worth Metroplex. Exited to
Advanced Total Management
Co-founder. Pharmaceutical wholesale distribution business. Exited to
Next Health (LinkedIn).Infinity Toxicology LLC
Co-founder. CLIA Highly Complex toxicology laboratory. Exited to Critical Healthcare Ltd, UK.
Expert witness practice formalized
Began regular retention as healthcare compliance expert witness in matters involving FDA, HIPAA, AKS, Stark, and OIG. Practice continues nationwide.
Andrew Hillman Scholarship and Grant in development
The Andrew Hillman Scholarship for Entrepreneurs and the Andrew Hillman Grant for Biotech are in development. Details to be announced.
Targeted Osmotic Lysis partnership with
an academic medical foundation
Formalized a research partnership with an academic medical foundation for the TOL platform. TOL is investigational. It is not approved by the FDA for any use and has not been shown to be safe or effective in humans.
- Targeted Osmotic Lysis is investigational. It is not approved by the FDA for any indication, it has not been shown to be safe or effective in humans, and it is not available as a treatment. No clinical trial of it is registered on ClinicalTrials.gov.
The Hillman Letter launches
Long-form publication on Substack covering FDA regulatory strategy, frontier therapeutics, and capital decisions in healthcare. Weekly cadence.